Clinical Trial Update: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating toripalimab in combination with nab-paclitaxel for metastatic or recurrent triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (Abraxane) (nab-paclitaxel)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: COMPLETED